Clinical Trials Logo

Relapsed Pediatric AML clinical trials

View clinical trials related to Relapsed Pediatric AML.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04562792 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Start date: May 8, 2020
Phase: Phase 2
Study type: Interventional

In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.